GSK said on Monday that a combination of its cancer drugs Zejula and Jemperli, when as used as a maintenance therapy following Jemperli plus chemotherapy, met the main goal of a late-stage trial to treat a certain type of endometrial cancer. The results from the trial showed that Jemperli plus chemotherapy followed by Jemperli and Zejula improved progression-free survival, compared …
Read More »GSK’s cancer drug combination meets primary goal
December 18, 2023